You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 7,351,701


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,351,701 protect, and when does it expire?

Patent 7,351,701 protects RUBRACA and is included in one NDA.

This patent has fifty-nine patent family members in twenty-four countries.

Summary for Patent: 7,351,701
Title:Therapeutic compounds
Abstract: The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
Inventor(s): Helleday; Thomas (Stockholm, SE), Curtin; Nicola (Tyne and Wear, GB)
Assignee: Cancer Research Technology Limited (London, GB) Pfizer, Inc. (New York, NY)
Application Number:10/898,653
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 7,351,701: A Deep Dive into Rucaparib

Introduction

United States Patent 7,351,701, filed on July 23, 2004, is a pivotal patent in the portfolio of rucaparib, a powerful poly (ADP-ribosyl) transferase (PARP) inhibitor. This patent is crucial for understanding the strategic protection and development of rucaparib, particularly in the context of cancer treatment. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Background of Rucaparib

Rucaparib, marketed under the trade name Rubraca, was first prepared and patented by the University of Newcastle in England in 2000. It was approved by the U.S. Food and Drug Administration (FDA) in April 2015 for the treatment of ovarian cancer and launched in the United States in December 2016[1].

Patent Overview: US 7,351,701

Filing and Grant

The patent US 7,351,701 was filed on July 23, 2004, and granted on April 1, 2008. This patent is part of the second stage of the patent portfolio for rucaparib, focusing on specific indications for the drug.

Claims and Scope

The patent claims the use of specific compounds, including rucaparib, for preparing medicines to treat cancers associated with BRCA1 and/or BRCA2 expression deficiencies. Here are the key aspects of the claims:

  • Compound Protection: The patent protects the application of three specific compounds in treating cancers. These compounds are part of the broader class of triyclic lactam indole derivatives and triacyclic lactam benzimidazole derivatives[5].
  • Disease Mechanism: The claims provide a detailed overview of the disease mechanism, specifically targeting BRCA1 and/or BRCA2 expression deficient cancer cells. This includes breast cancer and other cancers where these genetic deficiencies are prevalent[1].
  • Pharmacokinetics: The patent includes data on the pharmacokinetics of the compound, such as plasma and tumor concentrations in mice, which are crucial for understanding the drug's efficacy and safety profile[1].

Technical Details

  • Figure 6: This figure in the patent description illustrates the plasma and tumor concentrations of the compound and its pharmacokinetics on peripheral blood lymphocytes (pbl PARP) and SW620 xenograft (tumor PARP) in mice at different times. This data is essential for demonstrating the drug's bioavailability and therapeutic potential[1].

Patent Landscape

Patent Network

The protection of rucaparib involves a complex patent network designed to maximize the value of intellectual property. This includes multiple patents filed at different stages, each focusing on various aspects of the drug:

  • Core Patent: The basic core patent for rucaparib is US 6,495,541, which expired on January 10, 2020. This patent covers the compound and its composition[1].
  • Indication Patents: Following the core patent, several indication patents were filed, including US 7,351,701. These patents extend the protection to specific uses of the drug, such as treating BRCA1 and/or BRCA2 expression deficient cancer cells[1].

Expiration Dates and Generic Entry

The patent US 7,351,701 is set to expire on July 23, 2024. This expiration date is critical for generic manufacturers, as it marks one of the earliest opportunities for generic entry. However, the overall generic entry date for rucaparib is expected to be August 17, 2035, due to other patents and regulatory protections still in place[2].

Litigation and Challenges

There have been several patent litigation cases involving the patents protecting rucaparib, indicating strong interest in generic launch. Recent data suggest that 63% of patent challenges are decided in favor of the generic patent challenger, and 54% of successful challengers promptly launch generic drugs[2].

Strategic Importance

Extending Patent Protection

The strategy behind filing multiple patents, including US 7,351,701, is to extend the patent protection period of rucaparib. By creating a patent fortress around the drug, pharmaceutical companies aim to delay generic competition and maintain market exclusivity for as long as possible[1].

Market Impact

The expiration of key patents like US 7,351,701 can significantly impact the market dynamics for rucaparib. Generic entry can lead to reduced prices and increased competition, affecting the revenue streams of the original patent holders.

Industry Insights

Expert Views

Industry experts emphasize the importance of a robust patent portfolio in the pharmaceutical sector. "A strong patent portfolio is essential for protecting the significant investments made in drug research and development," notes a pharmaceutical industry expert. "It allows companies to recoup their investments and continue innovating without immediate generic competition"[1].

Statistics

  • Patent Family Members: Rucaparib has 234 patent family members in 43 countries, highlighting the extensive global protection strategy[2].
  • Litigation Outcomes: The high success rate of generic patent challengers underscores the need for pharmaceutical companies to continually strengthen and expand their patent portfolios[2].

Conclusion

United States Patent 7,351,701 is a critical component of the patent strategy for rucaparib, providing specific protection for the drug's use in treating BRCA1 and/or BRCA2 expression deficient cancers. Understanding the scope and claims of this patent, along with the broader patent landscape, is essential for both pharmaceutical companies and generic manufacturers.

Key Takeaways

  • Patent Scope: US 7,351,701 protects the use of rucaparib in treating BRCA1 and/or BRCA2 expression deficient cancers.
  • Expiration Date: The patent is set to expire on July 23, 2024.
  • Generic Entry: The earliest generic entry date is expected to be August 17, 2035, due to other patents and regulatory protections.
  • Strategic Importance: The patent is part of a broader strategy to extend patent protection and maintain market exclusivity.
  • Industry Impact: The expiration of this patent will have significant market implications, including potential generic competition and reduced prices.

FAQs

Q: What is the primary focus of United States Patent 7,351,701? A: The primary focus is the use of rucaparib in treating BRCA1 and/or BRCA2 expression deficient cancers.

Q: When was the patent filed and granted? A: The patent was filed on July 23, 2004, and granted on April 1, 2008.

Q: What is the expiration date of US 7,351,701? A: The patent is set to expire on July 23, 2024.

Q: How does this patent fit into the broader patent strategy for rucaparib? A: It is part of the second stage of the patent portfolio, focusing on specific indications for the drug to extend patent protection.

Q: What are the potential market implications of the patent's expiration? A: The expiration could lead to generic competition, reduced prices, and changes in market dynamics for rucaparib.

Sources

  1. Analysis of Strategy for Extending Patent Protection of Rucaparib - SCIRP
  2. RUBRACA Drug Patent Profile - DrugPatentWatch
  3. Patent Claims and Patent Scope - SSRN
  4. Cancer Drug Patents Expiring 2024-2028 - GreyB
  5. Therapeutic compounds - Patent US-7351701-B2 - PubChem

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 7,351,701

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmaand RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No ⤷  Subscribe ⤷  Subscribe A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION ⤷  Subscribe
Pharmaand RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No ⤷  Subscribe ⤷  Subscribe A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION ⤷  Subscribe
Pharmaand RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No ⤷  Subscribe ⤷  Subscribe A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.